Abstrak
Antiphospholipid Syndrome (APS), a thrombophilic condition, is being increasingly recognised as an important cause of recurrent pregnancy loss, preeclampsia and possible infertility. It could occur as a primary condition or it may be secondary to connective tissue diseases, infections or malignancies. Though recurrent pregnancy loss is a common feature of APS, there are other presentations attributable to thrombosis. The mechanism of thrombosis is still not completely understood but there are various suggested mechanisms. Presence of anti -cardiolipin antibodies (aCL) and lupus anticoagulant (LAC) are diagnostic. Management is variously with heparin, aspirin and warfarin, although other treatment modalities are being deployed. A high index of suspicion is needed for this otherwise treatable condition. Management is ideally best done by an obstetrician and a rheumatologist.
Keywords:- Antiphospholipid syndrome, recurrent pregnancy loss, review, management
Résumé
Le syndrome antiphospholipideique (SAP), une condition thrombophilique, est reconnu comme croissant et importante cause des pertes récurrentes des grossesses, pré-éclampsies et possible infertilité. Bien que la perte de grossesse récurrente est un caractéristique commun de l’APS, Ils ont d’autres signes attribuables a la thrombose. Le mécanisme de la thrombose n’est pas encore complètement compris mais plusieurs mécanismes ont été suggérés. La présence des anticorps anti -cardiolipine (aCL) et le lupus anticoagulant (LAC) sont diagnostiques. Le soin est varié avec l’héparine, aspirine et le warfarine, bien que d’autres modalités de traitement ont été déployées. Un indexe de suspicion élevé est nécessaire pour cette condition bien que traitable. Le traitement est le meilleur soin par un obstétricien et un rhumatologiste.
Correspondence: Dr. O.O. Adelowo, P.O. Box 7231, Ikeja, Lagos. Nigeria. E-mail: femiadelowo2003@yahoo.com
Referensi
Balasch J. Antiphospholipid antibodies; a major advance in the management of recurrent bortion. Autoimmun Rev. 2004; 3(3):228-233.
Hughes G. Hughes syndrome; the antiphospholipid syndrome: a clinical overview. Clin Rev Allergy Immunol. 2007; 32(1):3-12.
Harris EN. Syndrome of the Black Swan Br J Rheumatol. 1987; 26:1211-1214.
Branch DW and Silver RM. Criteria for antiphospholipid syndrome:early pregnancy loss,fetal loss,or recurrent pregnancy loss?. Lupus 1996;5(5): 409-413.
Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification for definite Antiphospholipid syndrome. Arthritis Rheum. 1999; 42:1309-1311.
Conley CL and Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952; 31: 621-622.
Harris EN. Antiphospholipid syndrome In: Klippel JH, Dieppe P (eds). Rheumatology 2nd edn. Mosby London.1997. pp [7] 35.1-6.
Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998; 77: 195-207.
Adelowo OO and Oguntona S. Antiphospholipid syndrome: Report of five cases. East Afr Med J. 2009; 86(2): 517-519.
Gezer S. Antiphospholipid syndrome Dis Mon. 2003; 49(12): 696-741.
Bertolaccini ML, Gomez S, Pareja JF et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis. 2005; 64: 1639-1643.
Vlachoyiannopoulos PG, Samarkos M and Tsiligros P. Antiphospholipid antibodies: Laboratory and pathogenetic aspects. Crit Review Clin Lab Sci. 2007; 44(3): 271-338.
Pierageli SS, Chen PP, Raschi E et al. Antiphospholipid antibodies and the Antiphospholipid: Pathogenetic mechanisms. Semin Thromb Hemost. 2008; 34(3): 236-250.
Rand JH. The pathogenic role of annexin V in the antiphospholipid syndrome. Clin Rheumatol Rep.2000;2(3): 246-251.
Cabriedes J, Cabral AR and Alarcon-Segovia D. Clinical manifestation of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti beta2 glycoprotein I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
Day HM, Thiagarajan P, Ahn C et al. Autoantibodies to beta 2 glycoprotein I in systemic lupus erythematosus and primary antiphospholipid syndrome: clinical correlates in comparison with other antiphospholipid antibody tests. J Rheumatol. 1998; 25:667-674.
Branch DW, Silver RM, Blackwell JL et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992; 80: 614-620.
Lockshin MD, Druzin ML and Oamar T. Prednisolone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol. 1989; 160: 439-443.
Cucurull E, Gharavi AE, Divi E et al. IgA anticardiolipin and beta 2 glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus Am J Med Sci 1999; 318: 55-66.
Balasch J, Creus M, Fabriques F et al. Antiphospholipid antibodies and human reproductive failure. Human Reprod. 1996; 11(10): 2310-2315.
Tebo AE, Jaskowski TD, Hill HR and Branch DW. Clinical relevance of multiple antibody testing in antiphospholipid syndrome and recurrent pregnancy loss. Clin Exp Immunol 2008; 154(3):332-338.
Carmo Pereira, Bertolaccini ML, Escudero-Contreras A, Khamashata MA and Hughes GR. Value of IgA anticardiolipin and anti beta 2 glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003; 62(6): 540-543.
Alijotas-Reig J, Casellas-Caro M, Ferrer-Oliveras R et al. Are Anti beta glycoprotein I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin seronegative women? Am J. Reprod Immunol. 2008; 60(3): 229-237.
Carp HJ and Shoenfeld Y. Antiphospholipid antibodies and infertility. Clin Rev Allergy Immunol. 2007;32 (2):159-161.
Shehata HA, Nelson-Piercy C and Khamashta M. Management of pregnancy in antiphospholipid syndrome. Rheum Dis Clin North Am. 2001; 27: 643-659.
Khamashta MA, Cuadrado MI, Mujic F et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Eng J Med. 1995; 332(15): 393-397.
Ensom MH and Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. J Soc Gynecol Investig. 2004; 11(6): 377-383.
Rai R, Cohen H, Dave M and Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. Br Med J. 1997; 314(7076):253-257.
Farquharson RG, Quenby S and Greaves M. Antiphospholipid syndrome in pregnancy: a randomised controlled trial of treatment. Obstet Gynecol. 2002; 100(3): 408-413.
Stephenson MD, Ballem PJ, Tsang P et al. Treatment of Antiphospholipid antibody syndrome(APS) in pregnancy; a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004; 26(8): 729- 734.
Spinatto JA, Clark AL, Pierangeli SS and Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol. 1995; 172:690-694.
Branch DW, Peaceman AM, Druzin M et al. A multicenter placebo controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol 2000; 182(1): 122-127.
Benson EM. Immunologic manipulation for the threatened fetus. Thromb Res 2004; 114(5-6): 427-434.